Artesunate

Generic Name
Artesunate
Brand Names
Artesunate Amivas
Drug Type
Small Molecule
Chemical Formula
C19H28O8
CAS Number
88495-63-0
Unique Ingredient Identifier
60W3249T9M
Background

Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin.

Artesunate was granted FDA approval on 26 May 2020.

Indication

Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients.

Associated Conditions
Acute Uncomplicated Plasmodium Falciparum Malaria, Malaria, Cerebral, Severe Malaria
Associated Therapies
-
Clinical Trials
Related News

Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso

First Posted Date
2016-01-26
Last Posted Date
2019-07-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
112
Registration Number
NCT02663700
Locations
🇧🇫

Centre National de Recherche et de Formation sur le Paludisme - Research and Training, Ouagadougou, Kadiogo, Burkina Faso

A Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon

Phase 3
Completed
Conditions
Malaria
Interventions
Drug: Artesunate
Drug: Quinine
First Posted Date
2015-09-30
Last Posted Date
2015-10-01
Lead Sponsor
University of Yaounde 1
Target Recruit Count
238
Registration Number
NCT02563704

Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma

Phase 1
Terminated
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Artesunate
First Posted Date
2014-12-01
Last Posted Date
2021-10-27
Lead Sponsor
University Hospital, Ghent
Target Recruit Count
2
Registration Number
NCT02304289
Locations
🇧🇪

Dept. of Hepatology & Gastroenterology Ghent University Hospital, Ghent, East-Flandres, Belgium

Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria

Phase 4
Completed
Conditions
Anaemia
Interventions
Drug: artesunate
Drug: quinine
First Posted Date
2014-03-20
Last Posted Date
2015-06-01
Lead Sponsor
University of Oxford
Target Recruit Count
217
Registration Number
NCT02092766
Locations
🇨🇩

Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the

Assessment of Artesunate/Mefloquine in the Peruvian Amazon

Phase 4
Completed
Conditions
Malaria, Falciparum
Interventions
Drug: Artesunate
Drug: Mefloquine
First Posted Date
2014-03-12
Last Posted Date
2021-04-29
Lead Sponsor
Instituto Nacional de Salud. Peru
Target Recruit Count
45
Registration Number
NCT02084602
Locations
🇵🇪

NAMRU 6, Iquitos, Loreto, Peru

In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy

First Posted Date
2013-11-06
Last Posted Date
2017-05-11
Lead Sponsor
Global Emerging Infections Surveillance and Response System
Target Recruit Count
118
Registration Number
NCT01976780
Locations
🇰🇪

Walter Reed Project, Kombewa Clinic, Kisumu, Kenya

Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria

First Posted Date
2013-10-07
Last Posted Date
2018-02-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
70
Registration Number
NCT01955382
Locations
🇲🇱

Universite des Sciencies, Techniques et Technologies de Bamako, Bamako, Mali

Intravenous Artesunate and Malaria

Phase 4
Conditions
Malaria
Interventions
Drug: artesunate
Drug: Quinine
First Posted Date
2013-03-06
Last Posted Date
2013-03-06
Lead Sponsor
University of Khartoum
Target Recruit Count
80
Registration Number
NCT01805232
Locations
🇸🇩

Kassala, Kassala, Sudan

Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand

First Posted Date
2012-08-10
Last Posted Date
2013-01-25
Lead Sponsor
Mahidol University
Target Recruit Count
120
Registration Number
NCT01662700
Locations
🇹🇭

Kraburi Hospital, Ranong, Thailand

🇹🇭

Khunhan Hospital, Srisaket, Thailand

🇹🇭

Kap Choeng Hospital, Surin, Thailand

and more 1 locations

Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand

Not Applicable
Completed
Conditions
Plasmodium Falciparum Malaria
Interventions
Drug: Artesunate
Drug: Mefloquine
First Posted Date
2012-08-07
Last Posted Date
2012-08-07
Lead Sponsor
Armed Forces Research Institute of Medical Sciences, Thailand
Target Recruit Count
13
Registration Number
NCT01659281
Locations
🇹🇭

Vector Borne Diseases Control Units (VBDC, malaria clinics), Borai, Khaosaming and Muang districts, Trat, Thailand

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy